Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Neoadjuvant Therapy in Locally Advanced Cervical Cancer
NCT07088731Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Cervical Cancer (CC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07088731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07088731.